Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

  • In development
  • GID-TA10696
  • Expected publication date: TBC

Documents

Documents created during the development process.

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators